How Can We Help?
You are here:
< Back

The Institute for Safe Medication Practices (ISMP) is an American 501(c)(3) organization focusing on the prevention of medication errors and promoting safe medication practices.[1] It is affiliated with ECRI.[2]

Activities

Among others, ISMP maintains and disseminates a list of "do not crush" medications,[3] as well as clinical best practices.[4] The ISMP's Medication Safety Self-Assessment tool has been used in surveys of medication safety in hospitals in the United States and elsewhere.[5][6][7][8]

The ISMP frequently investigates and reports on medication errors that have occurred in practice. These investigations are often published in the peer-reviewed journal Hospital Pharmacy.[9][10][11]

References

  1. ^ Guidestar. "Institute for Safe Medication Practices". Guidestar by Candid. Retrieved 2021-06-30.
  2. ^ ECRI. "ECRI and the Institute for Safe Medication Practices (ISMP) Launch New Patient Safety Organization". www.prnewswire.com (Press release). Retrieved 2021-06-30.
  3. ^ Cohen, Michael R. (July 2007). ""Do Not Crush" list". Nursing2021. 37 (7): 12. doi:10.1097/01.NURSE.0000279404.54880.3a. ISSN 0360-4039.
  4. ^ "ISMP Publishes 2020-2021 Consensus-Based Medication Safety Best Practices for Hospitals". Institute For Safe Medication Practices. 27 February 2020. Retrieved 2021-06-30.
  5. ^ Lesar, Timothy; Mattis, Arnold; Anderson, Ernest; Avery, Jean; Fields, John; Gregoire, Jill; Vaida, Allen; VHA New England Medication Error Prevention Initiative Collaborative (2003-05-01). "Using the ISMP Medication Safety Self-Assessment™ to Improve Medication Use Processes". The Joint Commission Journal on Quality and Safety. 29 (5): 211–226. doi:10.1016/S1549-3741(03)29026-2. ISSN 1549-3741. PMID 12751302 – via Elsevier Science Direct.
  6. ^ Vaida, Allen J.; Lamis, Rebecca L.; Smetzer, Judy L.; Kenward, Kevin; Cohen, Michael R. (2014-02-01). "Assessing the State of Safe Medication Practices Using the ISMP Medication Safety Self Assessment® for Hospitals: 2000 and 2011". The Joint Commission Journal on Quality and Patient Safety. 40 (2): 51–AP3. doi:10.1016/S1553-7250(14)40007-2. ISSN 1553-7250. PMID 24716328.
  7. ^ Greenall, Julie; Shastay, Ann; Vaida, Allen J; U, David; Johnson, Philip E; O’Leary, Joe; Chambers, Carole (2015-02-01). "Establishing an international baseline for medication safety in oncology: Findings from the 2012 ISMP International Medication Safety Self Assessment® for Oncology". Journal of Oncology Pharmacy Practice. 21 (1): 26–35. doi:10.1177/1078155214556522. ISSN 1078-1552. PMID 25361598. S2CID 36967892.
  8. ^ McCarthy, Kaitlyn R.; Christakos, Eugenia; Kurzatkowski, Amy; Gernant, Stephanie A. (2021-07-01). "Characterizing perceptions of an abbreviated ISMP Medication Safety Self Assessment for community pharmacies". Journal of the American Pharmacists Association. 61 (4): S105–S117. doi:10.1016/j.japh.2021.02.013. ISSN 1544-3191. PMID 33812781. S2CID 233029198.
  9. ^ Mancano, Michael A.; Esordi, Morgan V.; Patel, Darshil D.; Milenki, Kristen J. (2019-04-01). "ISMP Adverse Drug Reactions: Longitudinal Thumbnail Fissures Due to Erlotinib Priapism Associated With the Use of ExtenZe Blindness From a Nevirapine-Based HAART Regimen Hyperprolactinemia and Galactorrhea Due to Aripiprazole Trypophobia Associated With Gabapentin Coadministered Linezolid and Methadone Cause Serotonin Syndrome". Hospital Pharmacy. 54 (2): 88–92. doi:10.1177/0018578718824449. ISSN 0018-5787. PMC 6431722. PMID 30923400.
  10. ^ Mancano, Michael A. (2018-02-01). "ISMP Adverse Drug Reactions: Influenza Vaccine–Induced Stevens-Johnson Syndrome; Vilazodone-Induced Nightmares; Dabigatran-Induced Pustular Eruptions; Neurotoxic and Cardiotoxic Symptoms After Cannabis Concentrate Exposure; Rosuvastatin-Induced Skin Eruption". Hospital Pharmacy. 53 (1): 15–17. doi:10.1177/0018578717739727. ISSN 0018-5787. PMC 5805017. PMID 29434381.
  11. ^ Mancano, Michael A.; Lapin, Jonathan; Paik, Andrew (2019-08-01). "ISMP Adverse Drug Reactions: Pheochromocytoma Crisis Induced by Metoclopramide Baclofen Dependence Following High-Dose Therapy Fatal Cardiotoxicity Following High-Dose Cyclophosphamide Acute Anterograde Amnestic Syndrome Induced by Fentanyl Ivermectin-Induced Toxic Epidermal Necrolysis Pembrolizumab-Induced Type 1 Diabetes". Hospital Pharmacy. 54 (4): 241–245. doi:10.1177/0018578719828860. ISSN 0018-5787. PMC 6628555. PMID 31320773.


Categories
Table of Contents